MedTrace Logo

The Role of Endogenous GIP in Glycosis Metabolism During Fasting

NCT06368752 · Status: ENROLLING_BY_INVITATION · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-04-16

No results posted yet for this study

Summary

This research project aims to investigate the role of endogenous GIP during fasting. With the infusion of a GIP receptor antagonist (GIP\[3-30\]NH2), is it possible to selectively remove the effect of endogenous GIP, and thus describe its effects by comparing it with what happens during a saline infusion.

Conditions

Interventions

BIOLOGICAL

GIP[3-30]NH2

GIP\[3-30\]NH2 is the naturally occurring shorter (truncated) variant of GIP\[1-42\]. GIP\[3-30\]NH2 also stimulates the GIP receptor and therefore acts like a GIP receptorantagonist

OTHER

Saline

Sodium chlorid with 0,5% human serum albumin.

Sponsors & Collaborators

  • Frederikke Koefoed-Hansen

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-04
Primary Completion
2023-12-12
Completion
2025-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06368752 on ClinicalTrials.gov